Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT Total Current Liabilities
All obligations due within one year.
Cogent Biosciences, Inc.NASDAQ: COGT
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities broadly unchanged from a year ago
Total current liabilities stood at $59.3M at the end of Q2 FY2026, up 1.5% from a year earlier and up 2.3% from the prior quarter. Over 3 fiscal years it compounded at +33.6% a year.
Context
- Total current liabilities amounted to 7.1% of total assets at the end of Q2 FY2026, down 14.2 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +1.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 63.95M USD
- Year-over-year change
- +14.8%
- 4-year CAGR
- +39.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.95M | +14.8% |
| FY2024 | 2024-12-31 | 55.71M | +46.0% |
| FY2023 | 2023-12-31 | 38.17M | +42.2% |
| FY2022 | 2022-12-31 | 26.85M | +57.2% |
| FY2021 | 2021-12-31 | 17.08M | — |
Total Current Liabilities vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's Jun 2026 total current liabilities of $59.3M is the 7th highest of the 10 companies compared; the peer median is $86.17M.
- Its year-over-year change of +1.5% is the 8th highest of 10, against a peer median of +14.1%.
- Total current liabilities amounts to 7.1% of total assets for COGT, versus a peer median of 10.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.31B | +2.6% | +9.4% | 16.7% | |
| Jun 2026 | $198M | -5.7% | +6.2% | 21.4% | |
| Aug 2026 | $130.74M | +58.8% | +7.0% | 10.9% | |
| Mar 2026 | $101.5M | +13.1% | +69.4% | 15.6% | |
| Mar 2026 | $86.17M | -8.9% | +60.5% | 18.2% | |
| Mar 2026 | $64.83M | +27.5% | +22.9% | 6.3% | |
| Jun 2026 | $59.3M | +1.5% | +33.6% | 7.1% | |
| Sep 2026 | $25.16M | +36.4% | -26.9% | 2.4% | |
| Mar 2026 | $25M | +93.0% | +45.9% | 7.2% | |
| Mar 2026 | $21.24M | +14.1% | +2.8% | 5.1% | |
| Peer median (excluding COGT) | $86.17M | +14.1% | +9.4% | 10.9% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 219.68M | 139.89M | 53.23M | 98.17M | 312.01M |
| Short-term Investments | 0 | 119.39M | 212.48M | 188.91M | 588.75M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.26M | 5.06M | 9.4M | 9.59M |
| Total Current Assets | 222.63M | 264.97M | 270.77M | 296.47M | 910.36M |
| Property, Plant & Equipment (Net) | 4.48M | 31.1M | 30.34M | 26.56M | 23.54M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.26M | 0 | 7.46M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.73M | 4.75M | 4.86M | 4.86M | 3.72M |
| Total Non-current Assets | 9.46M | 35.84M | 42.67M | 31.43M | 27.25M |
| Total Assets | 232.09M | 300.81M | 313.44M | 327.9M | 937.61M |
| Account Payables | 3.48M | 5.84M | 10.66M | 12.01M | 9.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.55M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 3.06M | 1.7M | 0 | 0 | 0 |
| Other Current Liabilities | 3.62M | 6.47M | 10.32M | 12.63M | 52.9M |
| Total Current Liabilities | 17.08M | 26.85M | 38.17M | 55.71M | 63.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 237.25M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (14.32M) |
| Total Non-current Liabilities | 831K | 18.23M | 17.47M | 15.9M | 237.28M |
| Total Liabilities | 17.91M | 45.08M | 55.64M | 71.61M | 301.24M |
| Common Stock | 44K | 70K | 86K | 110K | 161K |
| Retained Earnings | (270.97M) | (411.21M) | (603.62M) | (859.48M) | (1.19B) |
| Accumulated OCI | (0) | (104K) | 246K | 447K | 355K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 214.18M | 255.74M | 257.8M | 256.29M | 636.37M |
| Total Debt | 3.16M | 19.65M | 18.85M | 17.47M | 253.15M |
| Net Debt | (216.53M) | (120.24M) | (34.38M) | (80.7M) | (58.86M) |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.